Poor
Misaligned (Not On-Label)
Patient Risk:
Low
Summary
All extracted claims are unrelated to the provided FDA label sections and are assessed as absent from the label; therefore, there is no on-label support for any claim.
Category Scores
Accurate Statements
Unsupported Statements
Lipitor (atorvastatin) can potentially alter the aroma of wine.
Not supported by any provided FDA label section text.
Atorvastatin is the active ingredient in Lipitor.
Not supported by any provided FDA label section text.
Atorvastatin taken in high doses can bind with sulfurous compounds in wine, altering wine’s characteristic aroma.
Not supported by any provided FDA label section text.
A study reported that individuals taking high doses of atorvastatin were more likely to detect a medicinal or unpleasant flavor in red wines.
Not supported by any provided FDA label section text.
In the study, the red wines mentioned as being particularly affected were Cabernet Sauvignon and Merlot.
Not supported by any provided FDA label section text.
The Journal of Agricultural and Food Chemistry study associated atorvastatin with changes to wine’s sulfur-based compounds.
Not supported by any provided FDA label section text.
The impact of Lipitor on wine aroma is a topic of debate among researchers.
Not supported by any provided FDA label section text.
Some studies found no correlation between Lipitor use and altered wine aroma.
Not supported by any provided FDA label section text.
Some studies reported conflicting results regarding Lipitor use and altered wine aroma.
Not supported by any provided FDA label section text.
Contradictions
Important Omissions
No FDA-label aligned claims related to indications, dosing/administration, contraindications, boxed warnings, warnings/precautions, drug interactions, adverse reactions, or monitoring were provided; thus, clinically important label content was not addressed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims concern wine aroma/flavor and do not state label-based contraindications, dosing changes, or recognized safety warnings. However, they are unsupported by the provided FDA label, which creates potential for misinformation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Misaligned (Not On-Label)
Primary Issue
All claims are absent from the provided FDA label sections and are therefore unsupported by the label.
Suggested Improvement
Exclude the wine-aroma/flavor claims from label-aligned content, or clearly qualify them as non-label research findings with citations outside the FDA label; ensure only label-supported information is presented when claiming FDA-approved prescribing information alignment.